KIRITSY CHRISTOPHER P 4

What Happened
Christopher P. Kiritsy, a director of Palvella Therapeutics, was granted a derivative equity award on 2026-06-10 covering 3,000 shares. The filing reports a $0.00 per-share acquisition price (award/derivative) — total reported cash consideration $0. This is an equity grant (award), not a purchase or sale of stock.

Key Details

• Transaction date: 2026-06-10; filing date: 2026-06-12.
• Transaction type: Award/derivative (Form 4 code "A"); 3,000 shares granted at $0.00.
• Shares owned after transaction: not disclosed in the filing.
• Footnote: The award vests on the earlier of (i) the first anniversary of the grant date or (ii) the issuer's next annual meeting, subject to continued service.
• No indication in the filing that shares were sold or immediately exercised; this was a time‑based equity grant.

Context
This is a standard director equity award intended for compensation/retention. Derivative awards with $0.00 listed typically represent stock options, restricted stock units, or similar grants rather than an open‑market purchase or sale. Such grants do not by themselves signal buying or selling intent — they reflect compensation and vesting tied to continued board service.